CytomX Reports Q3 2026 Financial Results with Revenue and EPS Misses
CytomX (CTMX) reported third-quarter financial results for the period ending September 30, 2026, missing both top and bottom-line expectations. The company posted a GAAP earnings per share (EPS) of -$0.09, falling short of estimates by $0.01. Revenue for the quarter totaled $1.69 million, representing a significant year-over-year decline of 71.6% compared to the $6.0 million reported in the same period in 2025. This revenue figure missed analyst expectations by approximately $8.76 million.
Tickers: $CTMX
Topics: earnings miss GAAP EPS revenue decline